Press Releases

RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine

Notes to editors Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. RDIF has established joint strategic partnerships with leading international co-investors from over 18 countries attracting over $40 bn of capital. Further information can be found at rdif.ru For more information about the Sputnik vaccine please visit sputnikvaccine.com/ Stelis Biopharma Pvt. Ltd. (Stelis) is a vertically integrated biopharmaceutical company. Stelis offers end-to-end state-of-the-art CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. Its operations include R&D, process development, scale-up & end-to-end cGMP manufacturing capabilities from drug substance through drug product in all formats and packaging. Stelis is also developing select follow-on biologic products for global markets in niche and commercially attractive disease categories. Stelis has recently forayed into Vaccine manufacturing with a capability to do multiple vaccine types. Stelis’ state-of-the-art research & development facility and 200,000 sq. ft. fully integrated cGMP manufacturing facility are located in Bengaluru, India. Facilities cater to the development and cGMP manufacturing of biologics and injectables conforming to international standards. For more information visit www.stelis.com Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

THREAD and CureClick Partner to Accelerate Recruitment for Decentralized Clinical Trials

Seven Bridges Launches the GRAF™ Population Solution — Population-Specific Tools and Services to Enhance Genetic Variation Discovery

Bioinformatics methods suffer from a significant loss of accuracy when used on sequencing data from under-represented populations because the genetic information of such populations cannot be captured in the linear reference genome. The inherent bias in the industry’s current reference genome favors the European population. A pan-genome approach can provide significant improvements, but it is still suboptimal. The Seven Bridges GRAF Population Solution is ancestry-aware and, therefore, more accurate than both linear and pan-genome approaches.

VisualDx Now Available at Northeast Ohio Medical University

Baltimore Aircoil Company Highlights ENDURADRIVE® Fan System for Ideal Cooling in Mission-Critical Environments

ENDURADRIVE® Fan System provides peace of mind and unmatched reliability, thanks to its advanced design

Formedix Launches All-in-One Cloud-Based Clinical Metadata Repository and Study Automation Platform to Simplify and Expedite Clinical Trial Design and Build

Formedix announces today the launch of ryze, an innovative all-in-one cloud-based clinical metadata repository (MDR) and study automation platform, specifically developed to accelerate and streamline the design, build and submission of clinical trials in compliance with CDISC and NCI Controlled Terminology.

ObvioHealth and RedHill Biopharma Launch First in Kind Remote COVID-19 Therapy Trial Incorporating Highest Level of At-home Patient Monitoring to Date

Auxita and MyMeds&Me Announce Strategic Partnership to Deliver Integrated Digital Pharmacovigilance Capabilities

This partnership integrates MyMeds&Me’s validated safety data capture solution into Auxita, enabling healthcare providers, patient support programs and pharmaceutical companies to capture and manage data more efficiently.

CRISPR/Cas9 Gene Editing Service Now Available by the GutFlora Omics Platform

Alfa Chemistry Released Ion Sensor Materials for Analytical and Chromatography Applications

AARDEX and Schreiner MediPharm reinforce their collaboration to Enhance Medication Adherence Management

AARDEX Group, the world leader in medication adherence solutions, continues to build up its ecosystem and to bridge GMP to GCP world in Clinical Trials by reinforcing their strategic partnership with Schreiner MediPharm, a global specialist in innovative functional labels and smart packaging solutions for the pharmaceutical industry.

Vanessa Research Proudly Supported Rare Disease Day

Rare Disease Day is observed internationally on the last day of February to raise awareness regarding the 300 million people worldwide who are battling rare diseases. Vanessa Research proudly supported Rare Disease Day for the fourth consecutive year. Unlike years past, in 2021 events were virtual because of the ongoing global COVID-19 pandemic.

Shimmer Launches Pulse+ the First Line Extension for its Verisense® Wearable Sensing Platform for Clinical Trials

Shimmer’s Verisense platform can now measure clinical trial participants’ heart rate, oxygen saturation and emotional responses in addition to their activity and sleep levels.

New personalised therapeutics partner joins Repositive Cancer Model network

Repositive has today announced that Vivan Therapeutics, an innovative personalised therapeutics company, will be the next company to join its global network of cancer model partners. Vivan Therapeutics has unique experience in engineering drosophila ‘avatar’ models for cancer research and development unique experience in engineering drosophila ‘avatar’ models for cancer research and development.

CD Bioparticles Releases Chitosans for Research Use

CD Bioparticles launches a series of chitosans for global research communities to support drug delivery studies.

BOC Sciences Upgrades Organelle Fluorescent Probe Product List

108Labs Launches Colostrupedics™ Whole-Human Infant Formula with Secretory Antibodies

108Labs announces Colostrupedics™ whole-human infant formula, made possible with the discovery of novel secretory antibody biosynthesis. This is the first animal-free infant formula that exclusively comprises cell-cultured human milk molecules derived from human mammary cell agriculture and formulated with broadly-neutralizing human secretory antibodies.

Cytel’s East Bayes® Broadens & Simplifies Access to Complex Bayesian Clinical Trial Designs

Cytel has launched East Bayes®, an enhanced web-based extension of the East® platform that enables adoption of the most computationally intensive Bayesian clinical trial designs – without the need for powerful on-site computers.

Leinco Technologies, Inc. and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools

Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates, has signed a licensing agreement with La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system, to develop novel COVID-19 diagnostics tools.

PCR Biosystems launches advanced Bst Polymerase reagents for accelerated DNA and RNA amplification

PCR Biosystems have launched a range of IsoFast™ Bst Polymerase reagents for rapid, robust and sensitive DNA and RNA amplification. Without the need for high temperature denaturation or specialised thermocycling equipment, IsoFast™ Bst Polymerase enables faster results and can be used in the field. This makes it ideal for a range of applications including environmental and food pathogen testing and clinical diagnostics – including for qualitative detection of the SARS-CoV-2 nucleic acid.